RBC Capital Reiterates Outperform on Corbus Pharmaceuticals, Maintains $82 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Corbus Pharmaceuticals (NASDAQ:CRBP) and maintained a price target of $82.
August 07, 2024 | 3:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Corbus Pharmaceuticals and maintained a price target of $82.
The reiteration of an Outperform rating and a high price target of $82 by RBC Capital is a positive signal for investors, likely boosting short-term investor confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100